Dihexa
early lab and animal synaptogenic research peptide — not FDA-approved.
What it's for
Dihexa is a lab-made peptide analog related to angiotensin IV (into a vein) research, investigated for synaptogenic effects.
What it does for the body
It has been studied in cognitive and neurodegenerative research models. It is not approved to treat dementia or enhance cognition. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
Research suggests Dihexa may enhance hepatocyte growth factor (HGF)/c-Met signaling linked to synapse formation in animal models. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Dihexa is best treated as a research-interest topic. Early papers can be fascinating; they are not a green light for self-experimentation.
Studied for (literature interest)
- Brain research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Dihexa — FDA.gov search
- ClinicalTrials.gov search: Dihexa — U.S. clinical trials registry
- Drugs@FDA search: Dihexa — FDA drug database (if approved)
- PubMed search: Dihexa — NCBI PubMed
- PubMed Central search: Dihexa — NCBI PMC
Reference
No ref on file.